ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1420

Non-Use of Glucocorticoid and Osteoarthritis Absence As Predictors of Clinical Remission in AR

Salvador Loredo-Alanís1, David Vega-Morales2, Mario Garza-Elizondo1, Mario Garcia-Pompermayer3, Roberto Negrete-López1, Daniel Treviño-Montes1 and Diana Flores-Alvarado2, 1Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, 2Rheumatology, Hospital Universitario UANL, Monterrey, Mexico, 3Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterey, Mexico

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Clinical, glucocorticoids, Osteoarthritis, remission and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality

Session Type: Abstract Submissions (ACR)

Background/Purpose

The clinical evaluation of Rheumatoid arthritis (RA) is accomplished with compound indexes allowing better clinical decision. Clinical remission nowadays is an attainable target in the management of RA patients. Clinical remission associated factors are under investigation. 

Objetive: Determine which factors are associated with clinical remission by CDAI in a RA population (ACR/EULAR 2010)

Methods

From a rheumatologic diseases cohort  in a University Hospital we made an observational, descriptive, retrospective and cross-sectional study of 361 patientes with RA. We analized variables such as demographics, rheumatoid factor, Anti-Cyclic Citrullinated Peptide antibodies, erythrocyte sedimentation rate, C-reactive protein, treatment, clinical activity, visual analog scale, comorbidities, extra-articular manifestations and temporality of RA. CDAI was calculated. Remission was defined with a CDAI score of 2.8.

Results

361 patients were evaluated. Female sex was predominant (97.7%). Mean age was 51.4. Clinical remission was found in 40.2%. When patients with and without clinical remission were compared, we found significant differences in: non use of prednisone (p 0.0001), use of Non-steroidal anti-inflammatory drugs (NSAIDs) (p 0.012), use of tramadol (p 0.0001), absence of osteoarthritis (p 0.33) and BMI <25Kg/m2 (p 0.017). In multivariate analysis factors associated with reach clinical remission were: Non use of oral steroids (p 0.0001, OR 3.39 IC 2.05-5.63) and absence of osteoarthritis (p 0.025, OR 1.8, IC 1.007-3.048). It was found a negative association to reach clinical remission with use of NSAIDs (p 0.008, OR 0.292 , IC 0.117-0.73) and use of tramadol (p 0.003, OR 0.107 , IC 0.024-0.47).

Conclusion

According to our study the presence of OA in patients with RA is a factor that decreases the CDAI specificity for detecting clinical remission. This possibly related to the score given by the patient to the visual analog scale and the presence of painful joints secondary to OA, but not inflamed by RA activity. It is therefore important that clinicians consider these factors when evaluating clinical remission in RA.


Disclosure:

S. Loredo-Alanís,
None;

D. Vega-Morales,
None;

M. Garza-Elizondo,
None;

M. Garcia-Pompermayer,
None;

R. Negrete-López,
None;

D. Treviño-Montes,
None;

D. Flores-Alvarado,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/non-use-of-glucocorticoid-and-osteoarthritis-absence-as-predictors-of-clinical-remission-in-ar/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology